Today, Sientra announced that it has received FDA approval of its
portfolio of Silimed-brand silicone breast implants.
“The rigorous FDA regulatory approval
process, coupled with Silimed's 33-year successful worldwide
manufacturing record, provides assurance of safety, quality and
reliability to surgeons and patients in the U.S. when choosing from
Sientra's portfolio of silicone breast implants.”
"We are elated to receive FDA approval of our flagship portfolio of
silicone breast implants," said Hani Zeini, founder and chief executive
officer of Sientra. "This represents two significant milestones. Namely,
for the first time in 20 years, Sientra has successfully broken the
existing duopoly in the U.S. by offering surgeons and patients a new
choice. And today, Sientra becomes the first and only company in the
U.S. to provide a full portfolio of commercially-available breast
implants, including shaped implants in addition to standard round
implants."
Until now, and in contrast to the rest of the world, the only approved
breast implants in the U.S. market have been round implants with no
other choices for surgeons or patients. Sientra now fills this gap by
offering an innovative portfolio of breast implants, including shaped
implants, with a broad selection of sizes, profiles, projections, and
implant surfaces.
Mr. Zeini also emphasized, "The rigorous FDA regulatory approval
process, coupled with Silimed's 33-year successful worldwide
manufacturing record, provides assurance of safety, quality and
reliability to surgeons and patients in the U.S. when choosing from
Sientra's portfolio of silicone breast implants."